Shi Yu, Wen Dengpeng, Wang Hui, Zhang Puyue, Zhong Yanmei, Liu Donghao, Zhou Deqi
College of Acupuncture and Moxibustion and Tuina, Chengdu University of Traditional Chinese Medicine.
Beibei District Traditional Chinese Medicine Hospital of Chongqing.
Medicine (Baltimore). 2020 Aug 7;99(32):e21459. doi: 10.1097/MD.0000000000021459.
Assessing the effectiveness and safety of Tai Chi for coronavirus disease 2019 (COVID-19) in recovery period is the main purpose of this systematic review protocol.
The following electronic databases will be searched from inception to April 2020: MEDLINE, Ovid, EMBASE, the Cochrane Library, the Allied and Complementary Medicine Database, Chinese National Knowledge Infrastructure, Chinese Biomedical Literature Database, VIP Database and Wanfang Database. In addition, Clinical trial registries, like the Chinese Clinical Trial Registry, the Netherlands National Trial Register and ClinicalTrials.gov, will be searched for ongoing trials with unpublished data. No language restrictions will be applied. The primary outcome will be the time of disappearance of main symptoms (including fever, asthenia, cough disappearance rate, and temperature recovery time), and serum cytokine levels. The secondary outcome will be the accompanying symptoms (such as myalgia, expectoration, stuffiness, runny nose, pharyngalgia, anhelation, chest distress, dyspnea, crackles, headache, nausea, vomiting, anorexia, diarrhea) disappear rate, negative COVID-19 results rate on 2 consecutive occasions (not on the same day), CT image improvement, average hospitalization time, occurrence rate of common type to severe form, clinical cure rate, and mortality. Two independent reviewers will conduct the study selection, data extraction and assessment. Review manager software V.5.3 will be used for the assessment of risk of bias and data synthesis.
The results will provide a high-quality synthesis of current evidence for researchers in this subject area.
The conclusion of the study will provide an evidence to judge whether Tai Chi is effective and safe for COVID-19 in recovery period.
This protocol will not evaluate individual patient information or infringe patient rights and therefore does not require ethical approval. Results from this review will be disseminated through peer-reviewed journals and conference reports.PROSPERO registration number CRD42020181456.
评估太极拳对2019冠状病毒病（COVID-19）恢复期的有效性和安全性是本系统评价方案的主要目的。
从建库至2020年4月，将检索以下电子数据库：MEDLINE、Ovid、EMBASE、Cochrane图书馆、补充与替代医学数据库、中国知网、中国生物医学文献数据库、维普数据库和万方数据库。此外，还将检索临床试验注册库，如中国临床试验注册中心、荷兰国家试验注册库和ClinicalTrials.gov，以查找有未发表数据的正在进行的试验。不设语言限制。主要结局将是主要症状消失时间（包括发热、乏力、咳嗽消失率和体温恢复时间）以及血清细胞因子水平。次要结局将是伴随症状（如肌痛、咳痰、鼻塞、流涕、咽痛、气喘、胸闷、呼吸困难、啰音、头痛、恶心、呕吐、厌食、腹泻）消失率、连续2次（非同一天）COVID-19检测结果为阴性的比率、CT图像改善情况、平均住院时间、普通型转为重型的发生率、临床治愈率和死亡率。两名独立的评审员将进行研究筛选、数据提取和评估。将使用Review Manager软件V.5.3评估偏倚风险和进行数据合成。
结果将为本学科领域的研究人员提供当前证据的高质量综合。
本研究结论将为判断太极拳对COVID-19恢复期是否有效和安全提供依据。
本方案不会评估个体患者信息或侵犯患者权利，因此无需伦理批准。本综述的结果将通过同行评审期刊和会议报告进行传播。
PROSPERO注册号：CRD42020181456。
